Innovating to improve health worldwide

WIPO’s 38th Standing Committee on Patents: Patents and health

On 4 November 2026, IFPMA delivered a statement on patents and health at WIPO’s 38th Standing Committee on Patents. A robust, stable, and predictable intellectual property system supports research and development, investment, and voluntary partnerships needed to translate scientific discoveries into innovative medicines and vaccines. As users of the patent system, including the Patent Cooperation...

Statement delivered at the opening plenary of the WHO Fair Pricing Forum 2026

On 3 November 2026, IFPMA delivered a statement at the opening plenary of the WHO Fair Pricing Forum.

Statement on PABS Instrument at the ninth meeting of the Intergovernmental Working Group (IGWG 9) on the WHO Pandemic Agreement

On 2 November 2026, IFPMA delivered a statement at the ninth meeting of the Intergovernmental Working Group (IGWG 9) on the WHO Pandemic Agreement.

Industry commits to continued efforts to protect biodiversity at close of COP17

On the occasion of the 17th session of the Convention on Biological Diversity Conference of the Parties (COP17), Guilherme Cintra, Director, Innovation Policy, IFPMA said: “The pharmaceutical industry plays a central role in protecting health and recognizes that fulfilling this mission requires a healthy and biodiverse planet. “For this reason, we have long supported the...

76th WHO Regional Committee for Europe: Roadmap for action on artificial intelligence in health in the WHO European Region 2026–2033

On 29 October 2026, IFPMA delivered a statement on the roadmap for action on artificial intelligence in health in the WHO European Region 2026–2033 at the 76th WHO Regional Committee for Europe in Copenhagen. We welcome efforts by WHO EURO to establish a pragmatic set of priorities toward meaningfully advancing AI in health. These efforts...